WO2008030564A3 - Aglycosylated antibodies and methods of making and using those antibodies - Google Patents
Aglycosylated antibodies and methods of making and using those antibodies Download PDFInfo
- Publication number
- WO2008030564A3 WO2008030564A3 PCT/US2007/019553 US2007019553W WO2008030564A3 WO 2008030564 A3 WO2008030564 A3 WO 2008030564A3 US 2007019553 W US2007019553 W US 2007019553W WO 2008030564 A3 WO2008030564 A3 WO 2008030564A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- methods
- aglycosylated
- making
- those
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides methods of preparing aglycosylated antibodies, for instance aglycosylated antibodies with altered or restored effector functions, as well as antibodies prepared by these methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84343806P | 2006-09-08 | 2006-09-08 | |
US60/843,438 | 2006-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008030564A2 WO2008030564A2 (en) | 2008-03-13 |
WO2008030564A3 true WO2008030564A3 (en) | 2008-09-18 |
Family
ID=39157866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019553 WO2008030564A2 (en) | 2006-09-08 | 2007-09-07 | Aglycosylated antibodies and methods of making and using those antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008030564A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1642983A (en) | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | Antibodies against of C5aR and use thereof |
WO2009103113A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
JP2012515556A (en) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Stabilized Fc polypeptides with reduced effector function and methods of use |
DK2718322T3 (en) | 2011-06-06 | 2018-12-03 | Novo Nordisk As | THERAPEUTIC ANTIBODIES |
CA2976236A1 (en) * | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
BR112019001989A2 (en) | 2016-08-02 | 2019-08-20 | Visterra Inc | engineered polypeptides and uses thereof |
US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999054342A1 (en) * | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2004099249A2 (en) * | 2003-05-02 | 2004-11-18 | Xencor, Inc. | Optimized fc variants and methods for their generation |
WO2005018572A2 (en) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006088494A2 (en) * | 2004-07-12 | 2006-08-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using the same |
WO2007048077A2 (en) * | 2005-10-21 | 2007-04-26 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
US20070231329A1 (en) * | 2003-03-03 | 2007-10-04 | Xencor, Inc. | Fc Variants Having Increased Affinity for FcyRIIb |
WO2007146847A2 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
-
2007
- 2007-09-07 WO PCT/US2007/019553 patent/WO2008030564A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999054342A1 (en) * | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US20070231329A1 (en) * | 2003-03-03 | 2007-10-04 | Xencor, Inc. | Fc Variants Having Increased Affinity for FcyRIIb |
WO2004099249A2 (en) * | 2003-05-02 | 2004-11-18 | Xencor, Inc. | Optimized fc variants and methods for their generation |
WO2005018572A2 (en) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006088494A2 (en) * | 2004-07-12 | 2006-08-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using the same |
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2007048077A2 (en) * | 2005-10-21 | 2007-04-26 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
WO2007146847A2 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
Non-Patent Citations (7)
Title |
---|
LUND J ET AL: "Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 30, no. 8, 1 June 1993 (1993-06-01), pages 741 - 748, XP002325440, ISSN: 0161-5890 * |
LUND J ET AL: "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 1996, vol. 157, no. 11, 1 December 1996 (1996-12-01), pages 4963 - 4969, XP002484003, ISSN: 0022-1767 * |
SARMAY G ET AL: "MAPPING AND COMPARISON OF THE INTERACTION SITES ON THE FC REGION OF IGG RESPONSIBLE FOR TRIGGERING ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) THROUGH DIFFERENT TYPES OF HUMAN FCY RECEPTOR", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 29, no. 5, 1 January 1992 (1992-01-01), pages 633 - 639, XP000915240, ISSN: 0161-5890 * |
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AL, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 * |
WALKER M R ET AL: "AGLYCOSYLATION OF HUMAN IGG1 AND IGG3 MONOCLONAL ANTIBODIES CAN ELIMINATE RECOGNITION BY HUMAN CELLS EXPRESSING FCGAMMARI AND/OR FCGAMMARII RECEPTORS", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, vol. 259, no. 2, 1 January 1989 (1989-01-01), pages 347 - 353, XP008064058, ISSN: 0264-6021 * |
WRIGHT A ET AL: "Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3393 - 3402, XP002443678, ISSN: 0022-1767 * |
YAMAGUCHI YOSHIKI ET AL: "Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.", BIOCHIMICA ET BIOPHYSICA ACTA APR 2006, vol. 1760, no. 4, April 2006 (2006-04-01), pages 693 - 700, XP002484004, ISSN: 0006-3002 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008030564A2 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007130697A3 (en) | Anti-ephb4 antibodies and methods using same | |
WO2008060705A3 (en) | Anti-dll4 antibodies and methods using same | |
WO2007133290A8 (en) | Anti-ox40l antibodies and methods using same | |
WO2008100805A3 (en) | Anti-robo4 antibodies and uses therefor | |
WO2006083936A3 (en) | Anti-ephb2 antibodies and methods using same | |
WO2008091954A3 (en) | Optimized cd40 antibodies and methods of using the same | |
WO2008017962A8 (en) | Microcapsules with improved shells | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
WO2008121616A3 (en) | Antibodies with decreased deamidation profiles | |
WO2009070243A3 (en) | Wise binding antibodies and epitopes | |
WO2006127757A3 (en) | Interferon-igg fusion | |
WO2007127841A3 (en) | Compositions and methods of preparation thereof | |
WO2008070344A3 (en) | Compositions and methods for binding sphingosine-1-phosphate | |
WO2007120334A3 (en) | Methods and compositions for targeting polyubiquitin | |
WO2007106744A8 (en) | Anti-5t4 antibodies and uses thereof | |
WO2009135181A3 (en) | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | |
WO2008002893A8 (en) | Anti-amyloid antibodies, compositions, methods and uses | |
WO2007136893A3 (en) | Anti-fgf19 antibodies and methods using same | |
WO2007014930A3 (en) | Polyammonium/polysiloxane copolymers | |
WO2007127506A3 (en) | Anti-ephrinb2 antibodies and methods using same | |
WO2008066630A3 (en) | Methods for reprogramming adult somatic cells and uses thereof | |
WO2008021342A3 (en) | Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone ) | |
WO2008048519A3 (en) | Antibodies that bind cxcr7 epitopes | |
WO2008025015A8 (en) | Epitope-protein scaffolds and their use | |
WO2007112279A3 (en) | Resonators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07811704 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07811704 Country of ref document: EP Kind code of ref document: A2 |